Myriad Genetics Inc (MYGN)

$5.34 -0.13 (-2.38%)
Market Cap 523.86M
Revenue (ttm) 837.60M
Net Income (ttm) -127.30M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -15.20%
Debt to Equity Ratio 0.32
Volume 1,021,400
Avg Vol 970,920
Day's Range N/A - N/A
Shares Out 93.21M
Stochastic %K 2%
Beta 1.81
Analysts Sell
Price Target $8.12

Company Profile

Myriad Genetics, Inc., a molecular diagnostic testing and precision medicine company, develops and provides molecular tests. The company offers molecular diagnostic tests for oncology, women's health, and pharmacogenomics. It also provides MyRisk Hereditary Cancer test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic test, a DNA sequencing test to help determine the therapy for metastatic breast, ovarian, metastatic pancreatic,...

Industry: Diagnostics & Research
Sector: Healthcare
Phone: 801 584 3600
Fax: 801 584 3640
Address:
322 North 2200 West, Salt Lake City, United States
Buster67
Buster67 Jan. 30 at 3:57 PM
$MYGN Buyers sellers cautious
0 · Reply
dillon95
dillon95 Jan. 29 at 7:55 PM
$MYGN Price remains rangebound
0 · Reply
SuperGreenToday
SuperGreenToday Jan. 24 at 1:38 AM
$MYGN Share Price: $5.88 Contract Selected: Aug 21, 2026 $8.0 Calls Buy Zone: $0.50 – $0.61 Target Zone: $0.86 – $1.05 Potential Upside: 63% ROI Time to Expiration: 209 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
Zrahimi
Zrahimi Jan. 20 at 5:19 PM
$MYGN back in $5.45 couldn’t help myself hoping for a bounce back up to six dollars sometime this week week
0 · Reply
MailBoxFull
MailBoxFull Jan. 17 at 2:58 AM
$MYGN doubt this stock moves… going to take rumors of a buyout.
0 · Reply
BillionerOfKing
BillionerOfKing Jan. 16 at 2:54 PM
$MYGN Current Stock Price: $5.91 Contracts to trade: $6.0 MYGN Jan 16 2026 Call Entry: $0.59 Exit: $0.78 ROI: 31% Hold ~31 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
Bulldozz
Bulldozz Jan. 15 at 11:31 PM
$TTD $MYGN bull
0 · Reply
BillionerOfKing
BillionerOfKing Jan. 15 at 2:06 AM
$MYGN Current Stock Price: $6.11 Contracts to trade: $6.0 MYGN Jan 16 2026 Call Entry: $0.59 Exit: $1.09 ROI: 84% Hold ~22 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Jan. 13 at 1:36 PM
$MYGN RSI: 50.70, MACD: -0.1489 Vol: 0.30, MA20: 6.57, MA50: 6.87 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
v92
v92 Jan. 12 at 2:12 PM
$MYGN LFG
0 · Reply
Latest News on MYGN
Myriad Genetics, Inc. (MYGN) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 14, 2026, 11:05 PM EST - 20 days ago

Myriad Genetics, Inc. (MYGN) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Myriad Genetics Announces Select Preliminary Fourth Quarter and Full Year 2025 Financial Results and Introduces Full Year 2026 Financial Guidance

Jan 12, 2026, 8:30 AM EST - 22 days ago

Myriad Genetics Announces Select Preliminary Fourth Quarter and Full Year 2025 Financial Results and Introduces Full Year 2026 Financial Guidance

Myriad Genetics to Present at 44th Annual J.P. Morgan Healthcare Conference

Jan 5, 2026, 4:15 PM EST - 4 weeks ago

Myriad Genetics to Present at 44th Annual J.P. Morgan Healthcare Conference

Clairity, Myriad Genetics, and MagView Launch the First Integrated AI and Genetic Risk Platform for Personalized Breast Health

Nov 25, 2025, 4:15 PM EST - 2 months ago

Clairity, Myriad Genetics, and MagView Launch the First Integrated AI and Genetic Risk Platform for Personalized Breast Health

Myriad Genetics to Participate in Upcoming Investor Healthcare Conferences

Nov 11, 2025, 9:00 AM EST - 3 months ago

Myriad Genetics to Participate in Upcoming Investor Healthcare Conferences

Myriad Genetics: Downgrading To "Hold" Rating On Break-Even Q3 Earnings

Nov 5, 2025, 1:36 PM EST - 3 months ago

Myriad Genetics: Downgrading To "Hold" Rating On Break-Even Q3 Earnings

Myriad Genetics, Inc. (MYGN) Q3 2025 Earnings Call Transcript

Nov 3, 2025, 11:56 PM EST - 3 months ago

Myriad Genetics, Inc. (MYGN) Q3 2025 Earnings Call Transcript

Myriad Genetics Reports Third Quarter 2025 Financial Results; Reiterates 2025 Financial Guidance Following Continued Solid Execution

Nov 3, 2025, 4:05 PM EST - 3 months ago

Myriad Genetics Reports Third Quarter 2025 Financial Results; Reiterates 2025 Financial Guidance Following Continued Solid Execution

New Post-Hoc Analysis Shows Patients Whose Clinicians Had Access to GeneSight Results for Depression Treatment Are More Likely to Feel Better Sooner

Oct 31, 2025, 9:05 AM EDT - 3 months ago

New Post-Hoc Analysis Shows Patients Whose Clinicians Had Access to GeneSight Results for Depression Treatment Are More Likely to Feel Better Sooner

Myriad Genetics to Release Third Quarter 2025 Financial Results on November 3, 2025

Oct 27, 2025, 4:15 PM EDT - 3 months ago

Myriad Genetics to Release Third Quarter 2025 Financial Results on November 3, 2025

Myriad Genetics Adds F8, FXN Genes to Foresight Universal Plus Panel

Oct 14, 2025, 8:00 AM EDT - 4 months ago

Myriad Genetics Adds F8, FXN Genes to Foresight Universal Plus Panel

Breast Cancer Awareness Month: Patient and Clinician Share Insights on how to tackle the fear of cancer screenings on YourUpdateTV

Oct 8, 2025, 5:21 PM EDT - 4 months ago

Breast Cancer Awareness Month: Patient and Clinician Share Insights on how to tackle the fear of cancer screenings on YourUpdateTV

Myriad Genetics and SOPHiA GENETICS to Develop an Innovative Companion Diagnostic Offering in Liquid Biopsy

Sep 23, 2025, 8:01 AM EDT - 4 months ago

Myriad Genetics and SOPHiA GENETICS to Develop an Innovative Companion Diagnostic Offering in Liquid Biopsy

SOPH

Myriad Genetics and SOPHiA GENETICS to Develop an Innovative Companion Diagnostic Offering in Liquid Biopsy

Sep 23, 2025, 8:00 AM EDT - 4 months ago

Myriad Genetics and SOPHiA GENETICS to Develop an Innovative Companion Diagnostic Offering in Liquid Biopsy

SOPH

Myriad Genetics, Inc. (MYGN) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Sep 10, 2025, 11:06 AM EDT - 5 months ago

Myriad Genetics, Inc. (MYGN) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Myriad Genetics Announces Precise MRD Clinical Data Published in The Lancet Oncology

Sep 4, 2025, 7:00 PM EDT - 5 months ago

Myriad Genetics Announces Precise MRD Clinical Data Published in The Lancet Oncology

New Meta-Analysis Demonstrates that Access to the GeneSight Test Can Significantly Improve Response and Remission Rates for Patients with Depression

Sep 3, 2025, 4:30 PM EDT - 5 months ago

New Meta-Analysis Demonstrates that Access to the GeneSight Test Can Significantly Improve Response and Remission Rates for Patients with Depression

Myriad Genetics Appoints Ben Wheeler Chief Financial Officer

Aug 18, 2025, 8:30 AM EDT - 6 months ago

Myriad Genetics Appoints Ben Wheeler Chief Financial Officer

New Myriad Genetics Survey Uncovers Women Fear Screenings—But Feel Reassured by the Results

Aug 13, 2025, 8:00 AM EDT - 6 months ago

New Myriad Genetics Survey Uncovers Women Fear Screenings—But Feel Reassured by the Results

Myriad: HCT In Oncology Continues To Deliver Increased Volume And Revenue Growth

Aug 6, 2025, 5:51 PM EDT - 6 months ago

Myriad: HCT In Oncology Continues To Deliver Increased Volume And Revenue Growth

Myriad Genetics, Inc. (MYGN) Q2 2025 Earnings Call Transcript

Aug 6, 2025, 4:14 AM EDT - 6 months ago

Myriad Genetics, Inc. (MYGN) Q2 2025 Earnings Call Transcript

Myriad Genetics Reports Second Quarter 2025 Financial Results; Raises 2025 Revenue Guidance Following Positive Business Momentum

Aug 5, 2025, 4:05 PM EDT - 6 months ago

Myriad Genetics Reports Second Quarter 2025 Financial Results; Raises 2025 Revenue Guidance Following Positive Business Momentum

Myriad Genetics Announces Early Access to the FirstGene Multiple Prenatal Screen

Jun 3, 2025, 9:00 AM EDT - 8 months ago

Myriad Genetics Announces Early Access to the FirstGene Multiple Prenatal Screen

Myriad Genetics Highlights New Research Advancements and Oncology Innovations at 2025 ASCO Annual Meeting

May 27, 2025, 4:05 PM EDT - 9 months ago

Myriad Genetics Highlights New Research Advancements and Oncology Innovations at 2025 ASCO Annual Meeting

Bronstein, Gewirtz & Grossman, LLC Encourages Myriad Genetics, Inc. (MYGN) Shareholders to Inquire about Securities Investigation

May 27, 2025, 10:00 AM EDT - 9 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Myriad Genetics, Inc. (MYGN) Shareholders to Inquire about Securities Investigation

Bronstein, Gewirtz & Grossman, LLC Is Investigating Myriad Genetics, Inc. (MYGN) And Encourages Shareholders to Connect

May 26, 2025, 10:00 AM EDT - 9 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Myriad Genetics, Inc. (MYGN) And Encourages Shareholders to Connect

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Myriad Genetics, Inc. (MYGN) And Encourages Shareholders to Reach Out

May 25, 2025, 10:00 AM EDT - 9 months ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Myriad Genetics, Inc. (MYGN) And Encourages Shareholders to Reach Out

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Myriad Genetics, Inc. (MYGN) and Encourages Shareholders to Learn More About the Investigation

May 23, 2025, 10:00 AM EDT - 9 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Myriad Genetics, Inc. (MYGN) and Encourages Shareholders to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Myriad Genetics, Inc. (MYGN) and Encourages Investors to Learn More About the Investigation

May 22, 2025, 10:00 AM EDT - 9 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Myriad Genetics, Inc. (MYGN) and Encourages Investors to Learn More About the Investigation

Myriad Genetics, Inc. (MYGN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

May 21, 2025, 10:00 AM EDT - 9 months ago

Myriad Genetics, Inc. (MYGN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC Is Investigating Myriad Genetics, Inc. (MYGN) And Encourages Investors to Connect

May 20, 2025, 10:00 AM EDT - 9 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Myriad Genetics, Inc. (MYGN) And Encourages Investors to Connect

Bronstein, Gewirtz & Grossman, LLC Encourages Myriad Genetics, Inc. (MYGN) Stockholders to Inquire about Securities Investigation

May 19, 2025, 10:00 AM EDT - 9 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Myriad Genetics, Inc. (MYGN) Stockholders to Inquire about Securities Investigation

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Myriad Genetics, Inc. (MYGN) And Encourages Investors to Reach Out

May 16, 2025, 10:00 AM EDT - 9 months ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Myriad Genetics, Inc. (MYGN) And Encourages Investors to Reach Out

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Myriad Genetics, Inc. (MYGN) And Encourages Stockholders to Reach Out

May 15, 2025, 10:00 AM EDT - 9 months ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Myriad Genetics, Inc. (MYGN) And Encourages Stockholders to Reach Out

Updated: Myriad Genetics to Participate in Two Upcoming Investor Healthcare Conferences

May 14, 2025, 4:45 PM EDT - 9 months ago

Updated: Myriad Genetics to Participate in Two Upcoming Investor Healthcare Conferences

Bronstein, Gewirtz & Grossman, LLC Is Investigating Myriad Genetics, Inc. (MYGN) And Encourages Stockholders to Connect

May 14, 2025, 10:00 AM EDT - 9 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Myriad Genetics, Inc. (MYGN) And Encourages Stockholders to Connect

Myriad Genetics, Inc. (MYGN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation

May 13, 2025, 10:00 AM EDT - 9 months ago

Myriad Genetics, Inc. (MYGN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Myriad Genetics, Inc. (MYGN) and Encourages Stockholders to Learn More About the Investigation

May 12, 2025, 7:15 PM EDT - 9 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Myriad Genetics, Inc. (MYGN) and Encourages Stockholders to Learn More About the Investigation

Myriad Genetics, Inc. (MYGN) Q1 2025 Earnings Call Transcript

May 6, 2025, 11:35 PM EDT - 9 months ago

Myriad Genetics, Inc. (MYGN) Q1 2025 Earnings Call Transcript

Buster67
Buster67 Jan. 30 at 3:57 PM
$MYGN Buyers sellers cautious
0 · Reply
dillon95
dillon95 Jan. 29 at 7:55 PM
$MYGN Price remains rangebound
0 · Reply
SuperGreenToday
SuperGreenToday Jan. 24 at 1:38 AM
$MYGN Share Price: $5.88 Contract Selected: Aug 21, 2026 $8.0 Calls Buy Zone: $0.50 – $0.61 Target Zone: $0.86 – $1.05 Potential Upside: 63% ROI Time to Expiration: 209 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
Zrahimi
Zrahimi Jan. 20 at 5:19 PM
$MYGN back in $5.45 couldn’t help myself hoping for a bounce back up to six dollars sometime this week week
0 · Reply
MailBoxFull
MailBoxFull Jan. 17 at 2:58 AM
$MYGN doubt this stock moves… going to take rumors of a buyout.
0 · Reply
BillionerOfKing
BillionerOfKing Jan. 16 at 2:54 PM
$MYGN Current Stock Price: $5.91 Contracts to trade: $6.0 MYGN Jan 16 2026 Call Entry: $0.59 Exit: $0.78 ROI: 31% Hold ~31 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
Bulldozz
Bulldozz Jan. 15 at 11:31 PM
$TTD $MYGN bull
0 · Reply
BillionerOfKing
BillionerOfKing Jan. 15 at 2:06 AM
$MYGN Current Stock Price: $6.11 Contracts to trade: $6.0 MYGN Jan 16 2026 Call Entry: $0.59 Exit: $1.09 ROI: 84% Hold ~22 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Jan. 13 at 1:36 PM
$MYGN RSI: 50.70, MACD: -0.1489 Vol: 0.30, MA20: 6.57, MA50: 6.87 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
v92
v92 Jan. 12 at 2:12 PM
$MYGN LFG
0 · Reply
StockDoctorBio
StockDoctorBio Jan. 9 at 3:13 PM
$MYGN crazy at this market cap. Even at 4 times current stock price it would be undervalued compared to peers
0 · Reply
Bulldozz
Bulldozz Jan. 6 at 8:58 AM
$TTD $MYGN squeeze incoming based on last week calls activity. All the people who sold last month for wash sale are jumping in
0 · Reply
Zrahimi
Zrahimi Jan. 2 at 4:04 PM
$MYGN back to 7s in January
0 · Reply
ZacksResearch
ZacksResearch Dec. 30 at 1:27 PM
$MYGN: Can this genetic testing company leverage its strategy? 🔄 Despite a 53.7% drop in the past year, Myriad Genetics is making strategic moves with new product launches and a refreshed growth strategy in the $6B Cancer Care Continuum market. Their earnings have also delivered an average surprise of 185% over the last four quarters. Discover what could drive MYGN’s future growth here 👉 https://www.zacks.com/stock/news/2810039/should-myriad-genetics-stock-stay-in-your-portfolio-right-now?cid=sm-stocktwits-2-2810039-body-26720&ADID=SYND_STOCKTWITS_TWEET_2_2810039_BODY_26720
0 · Reply
ZacksResearch
ZacksResearch Dec. 30 at 12:14 PM
$MYGN at a crossroads — growth engines firing, but a key revenue headwind won’t go away. ⚖️ New genetic test launches and a refreshed CCC strategy point to real growth potential, but revenue pressure from GeneSight coverage loss is still weighing on results. See the full risk/reward setup here 👉 https://www.zacks.com/stock/news/2810039/should-myriad-genetics-stock-stay-in-your-portfolio-right-now?cid=sm-stocktwits-2-2810039-teaser-26707&ADID=SYND_STOCKTWITS_TWEET_2_2810039_TEASER_26707
0 · Reply
PriceTargetP
PriceTargetP Dec. 25 at 11:05 AM
$MYGN The next leg of valuation movement will likely hinge on how management navigates competing priorities. The market is increasingly intolerant of delays that stretch credibility. Aligned incentives and governance can stabilize expectations. Overall, the trajectory is less about vision and more about proving the operating model works.
0 · Reply
Cristig78
Cristig78 Dec. 19 at 6:12 AM
$MYGN https://www.tradingview.com/news/reuters.com,2025:newsml_FWN3XO16H:0-zydus-lifesciences-signs-agreement-with-myriad-genetics-for-cancer-risk-tests-in-india/
0 · Reply
madisonclark03
madisonclark03 Dec. 12 at 6:13 PM
$MYGN Mainz Biomed I’m leaning bullish as long as $1.00 keeps holding, because the chart is coiled and the catalyst themes are huge, screening funnel size 45+ age tailwind, ~4,000,000 UK invites, and a product profile citing 82% advanced adenomas
0 · Reply
PeakedSeller
PeakedSeller Nov. 21 at 5:16 PM
$MYGN returning back to pre earnings price since that drop was so unwarranted
0 · Reply
NVDAMillionaire
NVDAMillionaire Nov. 18 at 10:36 AM
$MYGN Brilliant piece that captures MYGN's situation perfectly. So if you want to update your understanding of MYGN or get to know MYGN better, this is essential reading. https://beyondspx.com/quote/MYGN/analysis/myriad-genetics-precision-growth-in-the-cancer-care-continuum-nasdaq-mygn
0 · Reply
Nhraracer
Nhraracer Nov. 11 at 6:18 PM
$MYGN
0 · Reply
JarvisFlow
JarvisFlow Nov. 11 at 5:04 PM
Piper Sandler updates rating for Myriad Genetics ( $MYGN ) to Overweight, target set at 9 → 8.5.
0 · Reply